ReviewIn vivo (Athens, Greece)2020
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Review in In vivo (Athens, Greece), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- A Houttuynia cordata-based Chinese herbal formula improved symptoms of allergic rhinitis during the COVID-19 pandemic.Journal of the Chinese Medical Association : JCMA · 2022Trial
- Epicardial adipose tissue in patients with and without COVID-19 infection.American heart journal plus : cardiology research and practice · 2025Article
- The unfolded protein response components IRE1α and XBP1 promote human coronavirus infection.mBio · 2023Article
- Intermediate monocytes expansion and homing markers expression in COVID-19 patients associate with kidney dysfunction.Clinical and experimental medicine · 2023Article
- Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19.Drug delivery and translational research · 2023Review
- Design and optimization of silymarin loaded in lyophilized fast melt tablets to attenuate lung toxicity inducedDrug delivery · 2022Article
- Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation.Histochemistry and cell biology · 2022Review
- IL-6 in the Ecosystem of Head and Neck Cancer: Possible Therapeutic Perspectives.International journal of molecular sciences · 2021Review
- Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences.International journal of molecular sciences · 2021Review
- Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics.Stem cell reviews and reports · 2021Review
- The Novel Coronavirus and Inflammation.Advances in experimental medicine and biology · 2021Review
- A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Drug repurposing and cytokine management in response to COVID-19: A review.International immunopharmacology · 2020Review
- Candesartan could ameliorate the COVID-19 cytokine storm.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020Article
- Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.International journal of molecular sciences · 2020Review
- Hematologic parameters in coronavirus infection (COVID-19) and their clinical implications.Discoveries (Craiova, Romania) · 2020Review
- Nine Cases of SARS-CoV-2-PCR-positive Samples Showed No Increase of Antibodies Against SARS-CoV-2.In vivo (Athens, Greece)Article
- A Nasopharyngeal Carcinoma Patient With COVID-19 Infection After Immunotherapy: A Case Report and Literature Review.In vivo (Athens, Greece)Article
- Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is viral respiratory infection with frequently fatal lung complications in the elderly or in people with serious comorbidities. Lung destruction appears to be associated with a cytokine storm related to an increased level of interleukin-6 (IL6). Therapeutic targeting of the interleukin-6 signaling pathway can attenuate such a cytokine storm and can be beneficial for patients with COVID-19 in danger of pulmonary failure. This article demonstrates the importance of IL6 in progression of disease and the possibility of inhibition of IL6 signaling in COVID-19 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.